Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients

Abdulraheem Yacoub • 26 Aug 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Parsaclisib Ruxolitinib

Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, discusses the potential addition of parsaclisib to ruxolitinib for the treatment of patients with myelofibrosis (MF). Dr Yacoub first highlights the promising activity that has been observed with the use of parsaclisib, and then gives an overview of clinical trials investigating this combination. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Abdulraheem Yacoub

2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021
3:10
Promising trials in polycythemia vera
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals